Ferulic acid sodium(Synonyms: 阿魏酸钠; Coniferic acid sodium)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Ferulic acid sodium (Synonyms: 阿魏酸钠; Coniferic acid sodium) 纯度: ≥99.0%

Ferulic acid sodium 是一种新型的成纤维细胞生长因子受体 1 (FGFR1) 抑制剂, 对于 FGFR1FGFR2IC50值分别为 3.78 and 12.5 μM。

Ferulic acid sodium(Synonyms: 阿魏酸钠; Coniferic acid sodium)

Ferulic acid sodium Chemical Structure

CAS No. : 24276-84-4

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ¥550 In-stock
100 mg ¥500 In-stock
1 g ¥650 In-stock
5 g ¥1800 In-stock
10 g   询价  
50 g   询价  

* Please select Quantity before adding items.

Ferulic acid sodium 相关产品

相关化合物库:

  • Natural Product Library Plus
  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • FDA-Approved Drug Library Mini
  • Bioactive Compound Library Plus
  • Immunology/Inflammation Compound Library
  • Kinase Inhibitor Library
  • Metabolism/Protease Compound Library
  • NF-κB Signaling Compound Library
  • Protein Tyrosine Kinase Compound Library
  • Stem Cell Signaling Compound Library
  • Natural Product Library
  • FDA-Approved Drug Library
  • Anti-Cancer Compound Library
  • Anti-Aging Compound Library
  • Drug Repurposing Compound Library
  • Antioxidants Compound Library
  • Reprogramming Compound Library
  • Oxygen Sensing Compound Library
  • Anti-Cardiovascular Disease Compound Library
  • Ferroptosis Compound Library
  • NMPA-Approved Drug Library
  • Medicine Food Homology Compound Library
  • Phenols Library
  • Pyroptosis Compound Library
  • Orally Active Compound Library
  • Traditional Chinese Medicine Monomer Library
  • FDA Approved & Pharmacopeial Drug Library
  • Anti-Lung Cancer Compound Library
  • Angiogenesis Related Compound Library
  • Mitochondria-Targeted Compound Library
  • Food Additive Library
  • Food-Sourced Compound Library
  • Anti-Liver Cancer Compound Library
  • Rare Diseases Drug Library

生物活性

Ferulic acid sodium is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC50s of 3.78 and 12.5 μM for FGFR1 and FGFR2, respectively.

IC50 & Target

IC50: 3.78 μM (FGFR1), 12.5 μM (FGFR2)[1].

体外研究
(In Vitro)

Ferulic acid (FA) is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC50s of 3.78 and 12.5 μM for FGFR1 and FGFR2, respectively. Ferulic acid exhibits great inhibitory activity on FGFR1 with an inhibitory rate of 92% at 1 µM. The proliferation of HUVEC stimulated by FGF1 is markedly decreased after Ferulic acid treatment ranging from 5 to 40 μM for 24 h. Ferulic acid does not exert significant cell viability up to 20 μM, but over 30 μM Ferulic acid exhibits a cytotoxic effect in HUVEC compare to the control. Ferulic acid inhibits FGF1-induced HUVEC migration and invasion in a dose-dependent manner. Ferulic acid markedly suppresses the FGF1-induced phosphorylation of PI3K and Akt. Ferulic acid treatments significantly inhibit MMP-2 and MMP-9 expression stimulated by FGF1[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Treatment with Ferulic acid (FA) potently inhibits FGF1-induced neovascularization. It is found that intragastric administration of Ferulic acid markedly inhibits tumor volume and tumor weight, as compare to the counterparts treated with DMSO. Furthermore, Ferulic acid treatment is well tolerated, and there is no significant difference in weight between the vehicle group and the FA-treated groups[1]. Ferulic acid (0.01, 0.1, 1 or 10 mg/kg) given by oral route decreases significantly the immobility time in the forced swimming test (FST) and tail suspension test (TST), whereas produces no effect in the open-field test. Results demonstrate that the administration of Ferulic acid (0.001 mg/kg, p.o.) boosts the antidepressant-like effect of fluoxetine (5 mg/kg, p.o.) in the TST[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

216.17

Formula

C10H9NaO4

CAS 号

24276-84-4

中文名称

阿魏酸钠;川芎素

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶解性数据
In Vitro: 

H2O : 100 mg/mL (462.60 mM; Need ultrasonic)

DMSO : 33.33 mg/mL (154.18 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 4.6260 mL 23.1299 mL 46.2599 mL
5 mM 0.9252 mL 4.6260 mL 9.2520 mL
10 mM 0.4626 mL 2.3130 mL 4.6260 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: PBS

    Solubility: 33.33 mg/mL (154.18 mM); Clear solution; Need ultrasonic

  • 2.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (11.56 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (11.56 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 3.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (11.56 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (11.56 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Yang GW, et al. Ferulic Acid Exerts Anti-Angiogenic and Anti-Tumor Activity by Targeting Fibroblast Growth Factor Receptor 1-Mediated Angiogenesis. Int J Mol Sci. 2015 Oct 12;16(10):24011-31.

    [2]. Zeni AL, et al. Ferulic acid exerts antidepressant-like effect in the tail suspension test in mice: evidence for the involvement of the serotonergic system. Eur J Pharmacol. 2012 Mar 15;679(1-3):68-74.

Cell Assay
[1]

HUVEC (5×104 cells/well) are plated onto a gelatinized 24-well culture plate and cultured in ECGS containing 15% FBS. HUVEC are treated with DMSO (0.1%) or different concentrations of Ferulic acid (FA) (0, 2.5, 5, 10, 20, 30, 40 μM) for 24 h. Cell viability is determined by the MTT assay. After 4 h of incubation, the absorbance is measured at 450 nm with a microplate reader. The results are calculated from six replicates of each experiment. Three independent experiments are performed[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[2]

Male Swiss mice (30 to 40 g) are maintained at 21 to 23°C with free access to water and food, under a 12:12 h light/dark cycle (lights on at 07:00 h). All manipulations are carried out between, 9:00 and 16:00 h, with each animal used only once. In order to investigate the antidepressant-like effect of Ferulic acid, Ferulic acid is administered at a dose range of 0.001 to 10 mg/kg, by oral route (p.o.) 60 min before the forced swimming test (FST), tail suspension test (TST) or open-field test. The control animals receive appropriate vehicle[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献
  • [1]. Yang GW, et al. Ferulic Acid Exerts Anti-Angiogenic and Anti-Tumor Activity by Targeting Fibroblast Growth Factor Receptor 1-Mediated Angiogenesis. Int J Mol Sci. 2015 Oct 12;16(10):24011-31.

    [2]. Zeni AL, et al. Ferulic acid exerts antidepressant-like effect in the tail suspension test in mice: evidence for the involvement of the serotonergic system. Eur J Pharmacol. 2012 Mar 15;679(1-3):68-74.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务